Clinical Trial Update: Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety and efficacy of palbociclib (CDK4/6 inhibitor) in patients with oligodendroglioma or recurrent oligoastrocytoma with preserved R…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oligoastrocytoma
• Oligodendroglioma

Drugs mentioned

• Palbociclib (palbociclib)

Snippet

Sponsor: Grupo Español de Investigación en Neurooncología | Conditions: Oligodendroglioma, Oligoastrocytoma | Phase 2 | Status: COMPLETED | Results posted: 2024-11-22